Each rare disease market is a complex “ecosystem” with interconnected groups of participants and stakeholders. For a biopharma company to succeed in any rare disease market, it must determine its role(s) within that ecosystem and figure out how to maximize the value it provides to all key stakeholder groups. In this paper, which is part I of a comprehensive series, we explore the RD ecosystem and the players that comprise it.
